Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
暂无分享,去创建一个
Jian-Hua Tong | Guang-Biao Zhou | Marion Jeanne | Guang-Biao Zhou | Saijuan Chen | Zhu Chen | Jihui Wu | J. Tong | H. de Thé | Hong Sun | Xiao-Jing Yan | Wenxue Liang | V. Lallemand-Breitenbach | Hong-Yu Hu | Xiao-Wei Zhang | Fei-Fei Yang | M. Jeanne | Hugues de Thé | Zhu Chen | Sai-Juan Chen | Qun-Ye Zhang | Qiuhua Huang | Valérie Lallemand-Breitenbach | Hong-Yu Hu | Xiao-Wei Zhang | Xiao-Jing Yan | Zi-Ren Zhou | Fei-Fei Yang | Zi-Yu Wu | Hong-Bin Sun | Wen-Xue Liang | Ai-Xin Song | Qun-Ye Zhang | Huai-Yu Yang | Qiu-Hua Huang | Yan Zhang | Ji-Hui Wu | A. Song | Zi-ren Zhou | Yan Zhang | Ziyu Wu | Huai-Yu Yang | Xiao-jing Yan
[1] A. Holmgren,et al. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide , 2007, Proceedings of the National Academy of Sciences.
[2] Wei Tang,et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.
[3] V. Lallemand-Breitenbach,et al. How acute promyelocytic leukaemia revived arsenic , 2002, Nature Reviews Cancer.
[4] Paul Freemont,et al. Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation , 2001, The Journal of experimental medicine.
[5] P. Freemont,et al. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] P. Pandolfi,et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation , 2008, Nature Medicine.
[7] Brent R. Martin,et al. Mammalian cell–based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity , 2005, Nature Biotechnology.
[8] Christine Chomienne,et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.
[9] Zhen-yi Wang,et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.
[10] E. Estey,et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.
[11] C. Niu,et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.
[12] Zhen-yi Wang,et al. Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.
[13] P. Freemont,et al. PML protein isoforms and the RBCC/TRIM motif , 2001, Oncogene.
[14] Jonathan D. Licht,et al. Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .
[15] D. E. Anderson,et al. Identification of arsenic-binding proteins in human breast cancer cells. , 2007, Cancer letters.
[16] Guang-Biao Zhou,et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.
[17] C. Natoli,et al. The MXAN procedure: a new method for analysing the XANES spectra of metalloproteins to obtain structural quantitative information. , 2003, Journal of synchrotron radiation.
[18] P. Freemont,et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. , 1999, Journal of cell science.
[19] P. Freemont,et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto‐oncoprotein PML. , 1995, The EMBO journal.
[20] H. de Thé,et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[21] Jiong Hu,et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.
[22] Yasuo Ikeda,et al. PML targeting eradicates quiescent leukaemia-initiating cells , 2008, Nature.
[23] M. Koken,et al. Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .
[24] M. Lei,et al. Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway , 2008, Nature Cell Biology.
[25] X. Le,et al. Interaction of trivalent arsenicals with metallothionein. , 2003, Chemical research in toxicology.
[26] M. Tatham,et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation , 2008, Nature Cell Biology.
[27] B. Rosen,et al. Spatial Proximity of Cys113, Cys172, and Cys422 in the Metalloactivation Domain of the ArsA ATPase* , 1996, The Journal of Biological Chemistry.
[28] A. Spuches,et al. Thermodynamics of the As(III)-thiol interaction: arsenite and monomethylarsenite complexes with glutathione, dihydrolipoic acid, and other thiol ligands. , 2005, Inorganic chemistry.